Main Article Content

Dr Sana
Dr Mumtaz Ali
Dr Kamlesh Kumar Ahuja
Dr Prince Misri Khan Kalhoro
Dr Vishamer Lal
Dr Deepak Lal


Atherosclerotic Cardiovascular Disease, Diabetes, HbA1C, LDL, HDL


Objectives: To determine the dyslipidemia pattern and assess the potential of lipid therapy in mitigating the risk of Atherosclerotic Cardiovascular Disease (ASCVD) among individuals with Diabetes.

Materials and Methods:  This retrospective study was conducted at Medical Unit 1, Chandka Medical College Hospital Larkana, Pakistan in the duration from July, 2023 to December, 2023. Data regarding biochemical, clinical, and pharmaceutical profiles were collected of 200 patients. The effectiveness of statin therapy was assessed in accordance with guidelines provided by the American Diabetes Association. Predesign questionere was used for collection of data.

Results: The mean age of total 200 patients was 50.13±11.74 years. Out of total 110 patients were male and the remaining 90 patients were female. The HbA1C level was assessed to be 8.17%, with a standard deviation of 0.96%. The mean LDL cholesterol level was 115.87 mg/dL with a standard deviation of 10.29 mg/dL. The mean HDL cholesterol level was 43.07 mg/dL with a standard deviation of 6.60 mg/dL. The mean triglyceride level was 127.79 mg/dL with a standard deviation of 22.56 mg/dL. LDL cholesterol levels were shown to be correlated with increased HbA1C. The numbers of patients requiring statin treatment, currently using statin medication, those under 40 in need of statin therapy, individuals under 40 receiving prescribed statin medication, and the total number of patients receiving sufficient lipid-lowering treatment were 194, 42, 151, 15, and 36, respectively.

Conclusion: The conclusion drawn from the study indicates that individuals in Pakistan diagnosed with type 2 diabetes frequently exhibit elevated LDL and reduced HDL cholesterol levels, placing many of them at a heightened risk of heart disease. It was further noted that a significant portion of these individuals could potentially improve their cardiovascular health by taking statins. However, the study also revealed that many of them are not currently taking these medications, highlighting a gap in treatment that could be addressed to enhance their overall health outcomes.

Abstract 77 | PDF Downloads 28


1. AAT H, Gillani SW, AAA M, Gulam SM. Safety and Efficacy Evaluation of Lipid Lowering Agents Use among Diabetes Patients: A Systematic Review of Literature. International Medical Journal. 2020;27(6).
2. Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diabetes and Vascular Disease Research. 2019;16(2):118-27.
3. Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, et al. Diabetes and lipid metabolism. Hormones. 2018;17:61-7.
4. Wengrofsky P, Lee J, Makaryus AN. Dyslipidemia and its role in the pathogenesis of atherosclerotic cardiovascular disease: implications for evaluation and targets for treatment of dyslipidemia based on recent guidelines. Dyslipidemia: IntechOpen; 2019.
5. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327-39.
6. Daya R, Bayat Z, Raal F. Prevalence and pattern of dyslipidaemia in type 2 diabetes mellitus patients at a tertiary care hospital. Journal of Endocrinology, Metabolism and Diabetes of South Africa. 2017;22(3):31–5-–5.
7. Rosenblit PD. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition. Current diabetes reports. 2019;19(8):61.
8. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2020 executive summary. Endocrine Practice. 2020;26(1):107-39.
9. Garshick M, Underberg JA. The use of primary prevention statin therapy in those predisposed to atherosclerosis. Current atherosclerosis reports. 2017;19:1-8.
10. Geldsetzer P, Manne-Goehler J, Theilmann M, Davies JI, Awasthi A, Danaei G, et al. Geographic and sociodemographic variation of cardiovascular disease risk in India: a cross-sectional study of 797,540 adults. PLoS medicine. 2018;15(6):e1002581.
11. Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clinical research in cardiology. 2017;106:237-48.
12. Enkhmaa B, Surampudi P, Anuurad E, Berglund L. Lifestyle changes: effect of diet, exercise, functional food, and obesity treatment on lipids and lipoproteins. Endotext [Internet]. 2018.
13. Eckel RH, Bornfeldt KE, Goldberg IJ. Cardiovascular disease in diabetes, beyond glucose. Cell metabolism. 2021;33(8):1519-45.
14. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. Jama. 2002;287(19):2570-81.
15. Rosenblit PD. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition. Current diabetes reports. 2019;19:1-20.
16. Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC rheumatology. 2018;2:1-14.
17. Yaqoob N, Roomi FS, Memon BG, Asim F, Nisar S. CORRELATION OF LIPID PROFILE IN DIABETES PATIENTS: THE POTENTIAL FOR RISK REDUCING OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. Journal of Population Therapeutics and Clinical Pharmacology. 2024;31(2):723-7.
18. Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert review of clinical pharmacology. 2018;11(10):959-70.

Most read articles by the same author(s)